

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: December 4, 2003 (Use as many sheets as necessary)		<b>Complete if Known</b>	
Application Number		09/679,147	
Filing Date		10/05/2000	
First Named Inventor		Tomoki TODO	
Group Art Unit		1632	
Examiner Name		Anne Marie Sabrina Wehbe	
Attorney Docket Number		066683-0190	

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A1	KOBY et al., "Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207)," The FASEB Journal, Vol. 13, August 1999, pp. 1325-1334	
	A2	WALKER et al., "Local and Systemic Therapy of Human Prostate Adenocarcinoma with Conditionally Replicating Herpes Simplex Virus Vector G207," Human Gene Therapy, Vol. 10, September 1, 1999, pp. 2237-2243	
	A3	Oyama et al., "Intravesical and Intravenous Therapy of Human Bladder Cancer by the Herpes Vector G207," Human Gene Therapy, Vol. 11, August 10, 2000, pp. 1683-1693	
	A4	CAREW et al., "Selective Infection and Cytolysis of Human Head and Neck Squamous Cell Carcinoma with Sparing of Normal Mucosa by a Cytotoxic Herpes Simplex Virus Type 1 (G207), Human Gene Therapy, , Vol. 10, July 1, 1999, pp. 1599-1606	
	A5	DELMAN et al., "Effects of Preexisting Immunity on the Response to Herpes Simplex-Based Oncolytic Viral Therapy, Human Gene Therapy, Vol. 11, December 10, 2000, pp. 2465-2472	
	A6	BENNETT et al., "Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer," J. Mol. Med, Vol. 78, 2000, pp. 166-174	
	A7	COZZI et al., "Intravesical oncolytic viral therapy using attenuated, replication-competent, herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model," The FASEB Journal, express article 10.1096/fj. 00-0533 fje, published on line march 5, 2001.	
	A8	EBRIGHT et al., "Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model," The Journal of Thoracic and Cardiovascular Surgery, Vol. 1124, 2002, Number 1	

Examiner Signature		Date Considered	2/10/04
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.